Suppr超能文献

[抗抑郁药和镇静剂对基层医疗中团体跨诊断认知行为疗法疗效的影响]

[The effect of antidepressants and sedatives on the efficacy of transdiagnostic cognitive behavioral therapy in groups in primary care].

作者信息

Eriksson Erik Brynjar Schweitz, Kristjansdottir Hafrun, Sigurdsson Jon Fridrik, Agnarsdottir Agnes, Sigurdsson Engibert

出版信息

Laeknabladid. 2013 Nov;99(11):505-10. doi: 10.17992/lbl.2013.11.517.

Abstract

BACKGROUND

Cognitive behavioral therapy (CBT) and SSRI/SNRI antidepressants have proven to be effective treatments for anxiety and depression. The gain from combined CBT and antidepressant therapy has in some studies been greater than from monotherapy. Benzodiazepines may interfere with the efficacy of individual CBT-treatment. We examined the effects of SSRI/SNRI antidepressants and the effects of benzodiazepines/z-drugs on the efficacy of group CBT (gCBT) in primary care.

MATERIAL AND METHODS

Primary outcome measures were the Beck's Depression Inventory II (BDI-II) and the Beck's Anxiety Inventory (BAI) scores before treatment and after the last session. The last observed score was carried forward and compared to the initial score for each individual, irrespective of the timing of the last score (LOCF). Mean change of scores was compared between groups of individuals on or not on SSRI/SNRI antidepressants and/or benzodiazepines/z-drugs.

RESULTS

Over three years 557 subjects participated in a 5 week-long gCBT. Of these 355 returned BDI-II and 350 returned BAI at least twice. The mean score on SSRI/SNRI or benzo/z-drugs fell significantly both for those on combined treatment (medication and gCBT) and those who only received gCBT. Combined treatment with SSRI/SNRI and gCBT led to a greater fall in depressive symptoms compared to gCBT monotherapy. The efficacy of such combined treatment was less for those who also were prescribed benzodiazepines and/or z-drugs.

CONCLUSIONS

Group CBT significantly improved symptoms of anxiety and depression in primary care. The improvement was not reduced by concomitant use of SSRI/SNRI antidepressants nor of benzodiazepines/z-hypnotics. The use of such medication is therefore not contraindicated for gCBT participants, at least not short term. Adding SSRIs or SNRIs to gCBT led to greater efficacy in reducing depressive symptom though the efficacy of such combined treatment was less for those who were also prescribed benzodiazepines and/or z-hypnotics.

摘要

背景

认知行为疗法(CBT)和选择性5-羟色胺再摄取抑制剂/5-羟色胺-去甲肾上腺素再摄取抑制剂(SSRI/SNRI)类抗抑郁药已被证明是治疗焦虑症和抑郁症的有效方法。在一些研究中,CBT与抗抑郁药联合治疗的效果优于单一疗法。苯二氮䓬类药物可能会干扰个体CBT治疗的疗效。我们研究了SSRI/SNRI类抗抑郁药以及苯二氮䓬类药物/非苯二氮䓬类催眠药对基层医疗中团体认知行为疗法(gCBT)疗效的影响。

材料与方法

主要结局指标为治疗前及最后一次治疗后贝克抑郁量表第二版(BDI-II)和贝克焦虑量表(BAI)的评分。将最后观察到的评分结转,并与每个个体的初始评分进行比较,无论最后评分的时间如何(末次观察值结转法,LOCF)。比较服用或未服用SSRI/SNRI类抗抑郁药和/或苯二氮䓬类药物/非苯二氮䓬类催眠药的个体组之间的评分平均变化。

结果

在三年时间里,557名受试者参加了为期5周的gCBT。其中,355人至少两次返回BDI-II评分,350人至少两次返回BAI评分。联合治疗组(药物治疗和gCBT)以及仅接受gCBT治疗的患者,其SSRI/SNRI类药物或苯二氮䓬类药物/非苯二氮䓬类催眠药的平均评分均显著下降。与gCBT单一疗法相比,SSRI/SNRI与gCBT联合治疗导致抑郁症状有更大程度的减轻。对于同时服用苯二氮䓬类药物和/或非苯二氮䓬类催眠药的患者,这种联合治疗的疗效较差。

结论

团体认知行为疗法在基层医疗中显著改善了焦虑和抑郁症状。同时使用SSRI/SNRI类抗抑郁药或苯二氮䓬类药物/非苯二氮䓬类催眠药并不会降低这种改善效果。因此,至少在短期内,gCBT参与者使用此类药物并无禁忌。在gCBT中添加SSRI或SNRI可提高减轻抑郁症状的疗效,尽管对于同时服用苯二氮䓬类药物和/或非苯二氮䓬类催眠药的患者,这种联合治疗的疗效较差。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验